Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)
Articolo
Data di Pubblicazione:
2022
Citazione:
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study) / Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Bandello, Francesco; Kuppermann, Baruch D; Loewenstein, Anat. - In: EYE. - ISSN 1476-5454. - 36:5(2022), pp. 1106-1107. [10.1038/s41433-021-01616-9]
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Bandello, Francesco; Kuppermann, Baruch D; Loewenstein, Anat
Link alla scheda completa:
Pubblicato in: